# Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

> **NCT03421288** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest** · enrollment: 677 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Calciumfolinat
- **DRUG:** Oxaliplatin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03421288
- **Lead sponsor:** Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-14
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 677 (ACTUAL)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03421288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03421288, "Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03421288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*